The end of the official shortage status for semaglutide came as telehealth company Hims & Hers – which has been pushing sales of compounded semaglutide hard and lambasting the pharma industry for restricting access to GLP-1 drugs – bought a peptide facility to raise its manufacturing capacity, sparking a sharp drop in its share price.
With Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions of semaglutide are no longer allowed – for now.
7h
Hosted on MSNHims & Hers Retail Traders Eye Robust Post-Earnings Rebound Following Stock’s Worst Drop On Semaglutide UpdateHims & Hers Health Inc. (HIMS) stock tumbled over 25% on Friday, extending losses in after-hours trading after the U.S. Food and Drug Administration (FDA) officially resolved the semaglutide shortage.
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply squeeze on Novo Nordisk’s diabetes and obesity counterpa | The FDA has officially declared an end to the supply squeeze on Novo Nordisk’s GLP-1 drug semaglutide for diabetes and obesity in the U.
Semaglutide — the type 2 diabetes and weight loss medication sold under the brand names Ozempic and Wegovy — can expire. If you’ve ever given old milk a sniff, you know for yourself that expired things aren’t good.
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.
The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for compounding pharmacies to make copies of Ozempic and Wegovy.
The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and projected demand in the country, the Danish pharmaceutical company said.
The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can meet present and future demand, Novo Nordisk and the FDA announced. On Feb. 21,
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other Renaissance Technologies portfolio’s top stock picks.
Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ) that's also probably bad news for Hims & Hers Health ( HIMS -17.80%).
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity or overweight.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results